Cost of asthma inhalers
Pro Research Analysisby 
Searched over 200M research papers
Asthma Inhaler Costs: Global and Regional Perspectives
High Cost of Asthma Inhalers in High-Income Countries
Asthma inhalers, especially maintenance inhalers, are often very expensive in high-income countries. In the United States, the cost for a single inhaler can be upwards of $700 per month, even for those with health insurance. This high cost restricts access, leading to poor medication adherence and worse health outcomes for patients. Although pharmaceutical manufacturers offer discount programs and coupons, these are inconsistent and depend on insurance plans, making it difficult for patients to reliably reduce their out-of-pocket expenses .
Direct and Indirect Costs of Asthma Inhaler Use
The overall cost of managing asthma with inhalers includes both direct costs (such as the price of the inhaler and healthcare visits) and indirect costs (like lost productivity). In European countries such as Spain, Sweden, and the UK, the direct annual cost of managing asthma and COPD with commonly prescribed dry powder inhalers (DPIs) was estimated at hundreds of millions of euros. Poor inhalation technique, which is common with DPIs, adds significantly to these costs, both by increasing healthcare resource use and by reducing treatment effectiveness .
Cost and Affordability in Low- and Middle-Income Countries
In low- and middle-income countries (LMICs), the situation is even more challenging. Essential asthma inhalers are often unavailable and unaffordable. For example, a short-acting beta-agonist (SABA) inhaler can cost the equivalent of 1–4 days’ wages for the lowest-paid government worker, while inhaled corticosteroids (ICS) can cost 2–7 days’ wages, and combination inhalers (ICS-LABA) at least 6 days’ wages. Most countries do not meet the World Health Organization’s target for inhaler availability, making access to these essential medicines very limited .
Cost-Effectiveness of Different Inhaler Therapies
Studies show that certain inhaler therapies can be cost-effective despite their high upfront costs. For example, inhaled corticosteroids (ICS) for mild-to-moderate asthma increase total health costs but also improve quality of life and reduce hospitalizations, making them a good value for money . Triple therapy (adding a long-acting muscarinic antagonist to ICS-LABA) is also cost-effective for patients with moderate-to-severe asthma, especially in resource-limited settings .
Impact of Inhaler Type and Technology on Costs
Switching from metered-dose inhalers (MDIs) to dry powder inhalers (DPIs) can reduce both environmental impact and, depending on the scenario, overall costs. Over a 50-year period, substituting MDIs with DPIs could reduce global greenhouse gas emissions by up to 58% and may result in manageable or even reduced costs, depending on the social cost of carbon . Additionally, digital inhalers that monitor usage and support adherence can lead to significant long-term cost savings by reducing the need for expensive add-on therapies and improving disease control .
Cost-Effectiveness in Emergency and Pediatric Settings
In pediatric emergency departments, using metered-dose inhalers (MDIs) with spacers instead of nebulizers for asthma exacerbations is more effective and less costly, resulting in significant savings for hospitals and families .
Insurance, Guidelines, and Real-World Costs
Adopting updated asthma treatment guidelines, such as using ICS-formoterol inhalers as relievers, can reduce asthma exacerbations but may increase pharmacy costs. However, these higher pharmacy costs are often offset by lower medical costs due to fewer hospital visits and better disease control . Over-the-counter options like budesonide-formoterol could be a cost-saving alternative for underinsured adults, improving outcomes and reducing fatalities compared to less effective options like inhaled epinephrine .
Conclusion
The cost of asthma inhalers is a significant barrier to effective asthma management worldwide. High prices, limited availability, and inconsistent discount programs restrict access, especially in low- and middle-income countries. However, cost-effective strategies—such as improving inhaler technique, adopting digital inhalers, and following updated treatment guidelines—can help reduce the overall economic burden of asthma care and improve patient outcomes Lewis2016Wolf2023Van De Hei2023+7 MORE.
Sources and full results
Most relevant research papers on this topic
Long-term cost-effectiveness of digital inhaler adherence technologies in difficult-to-treat asthma.
Digital inhaler-based interventions can be cost-saving in the long term for patients with difficult-to-treat asthma by optimizing medication adherence and inhaler technique, and reducing add-on biologic prescriptions.
Cost-effectiveness of budesonide-formoterol versus inhaled epinephrine in United States adults with mild asthma.
OTC as-needed budesonide-formoterol for treating mild asthma in underinsured adults without HCP management improves asthma outcomes, prevents fatalities, and is cost-saving.
DOI